|Title:||EGFR-Mutant SCLC Exhibits Heterogeneous Phenotypes and Resistance to Common Antineoplastic Drugs||Authors:||Lin, Chih-An
|Keywords:||EGFR-activating mutation; EGFR-tyrosine kinase inhibitors; Histone deacetylase; Resistance; Small cell lung cancer||Issue Date:||2019||Publisher:||ELSEVIER SCIENCE INC||Journal Volume:||14||Journal Issue:||3||Start page/Pages:||513||Source:||Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer||Abstract:||
Approximately 5% of patients with EGFR-activating mutations acquire EGFR tyrosine kinase inhibitor (TKI) resistance through SCLC transformation. However, the reason for the poor outcome and the molecular basis of EGFR-mutant SCLC that has transformed from adenocarcinoma remain unclear.
|Appears in Collections:||毒理學研究所|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.